Evidence map›Paper›PMID 34188447›Full record

ArticleDrug design, development and therapy2021

Prospective Application of Two New Pyridine-Based Zinc (II) Amide Carboxylate in Management of Alzheimer's Disease: Synthesis, Characterization, Computational and in vitro Approaches.

Rehman Zafar, Humaira Naureen, Muhammad Zubair, Khadija Shahid, Muhammad Saeed Jan, Samar Akhtar, Hammad Ahmad, Wajeeha Waseem, Ali Haider, Saqib Ali and 2 more

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Design, Synthesis, SwissADME Profile DFT Studies,Current medicinal chemistry · 2026
    Article
  2. Mechanism of Metal Complexes in Alzheimer's Disease.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Rehman ZafarDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan.
Humaira NaureenDepartment of Pharmacognosy, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan.ORCID 0000-0003-2989-3175
Muhammad ZubairDepartment of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Khadija ShahidDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan.
Muhammad Saeed JanDepartment of Pharmacy, University of Swabi, Swabi, KP, Pakistan.ORCID 0000-0003-2411-6510
Samar AkhtarYusra Institute of Pharmaceutical Sciences, Islamabad, 44000, Pakistan.
Hammad AhmadYusra Institute of Pharmaceutical Sciences, Islamabad, 44000, Pakistan.
Wajeeha WaseemDepartment of Basic Medical Sciences, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan.
Ali HaiderDepartment of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Saqib AliDepartment of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Muhammad TariqDepartment of PCB, Rokhan University, Jalalabad, Nangrahar, Afghanistan.ORCID 0000-0002-5779-8370
Abdul SadiqDepartment of Pharmacy, University of Malakand, Chakdara, KP, Pakistan.
Riphah International University · PKQuaid-i-Azam University · PKNangarhar University · AFUniversity of Malakand · PKUniversity of Swabi · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a neurodegenerative illness described predominantly by dementia. Even though Alzheimer's disease has been known for over a century, its origin remains a mystery, and researchers are exploring many therapy options, including the cholinesterase technique. A decreased acetylcholine ACh neurotransmitter level is believed to be among the important factors in the progression of Alzheimer's disease.

methodsIn continuation of synthesizing potential anti-Alzheimer agents and known appreciative pharmacological potential of amide-containing compounds, this study presents the synthesis of two novel amide-based transition metal zinc (II) complexes, AAZ7 and AAZ8, attached with a heterocyclic pyridine ring, which was synthesized and characterized by Fourier transform infrared spectroscopy (FT-IR), elemental analysis,

resultsImportantly, the complex of AAZ8 exhibited more potent activity giving IC

conclusionHerein, we report two new amide carboxylate zinc (II) complexes which were potentially analyzed for various biological applications like acetylcholinesterase (AChE), butyrylcholinesterase (BChE) inhibitory potentials, and antioxidant assays. Computational docking studies also simulated results to understand the interactions. Additionally, thermodynamic parameters utilizing molecular dynamic simulation were performed to determine the ligand protein stability and flexibility that supported the results. Studies have shown that these compounds have the potential to be good anti-Alzheimer candidates for future studies due to inhibition of cholinesterase enzymes and display of free radical scavenging potential against DPPH as well as ABTS free radicals.

Indexed as

AcetylcholinesteraseAlzheimer DiseaseAmidesAnimalsAntioxidantsButyrylcholinesteraseCarboxylic AcidsCholinesterase InhibitorsElectrophorusFree Radical ScavengersHorsesInhibitory Concentration 50Molecular Docking SimulationPyridinesZincAcetylcholinesteraseAmidesAntioxidantsButyrylcholinesteraseCarboxylic AcidsCholinesterase InhibitorsFree Radical ScavengersPyridinesZincacetylcholinesterasebutyrylcholinesterasedocking studieselemental analysisZn(II) carboxylate

Identifiers

PMID34188447
PMCPMC8232895
OpenAlexW3174427493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.